Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by Therapeutic Solutions

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Umbilical cord derived mesenchymal stem cell

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: JadiCells

            Highest Development Status: Phase I Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 17, 2020

            Details:

            Company announced today filing of an IND application seeking permission from the Food and Drug Administration (FDA) to initiate a Phase I/II clinical trial assessing safety and signals of efficacy for treatment of Chronic Traumatic Encephalopathy (CTE) patients with JadiCells.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Pterostilbene,Epigallocatechin Gallate,Sulforaphane

            Therapeutic Area: Infections and Infectious Diseases Product Name: QuadraMune

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 24, 2020

            Details:

            Using a standard test for natural killer cell activity, the K562 lysis assay, 12 healthy volunteers taking one week of placebo had an average activity of 2.3 (±0.6), whereas those taking one week of QuadraMune™ had an average activity of 5.2 (±1.2), almost double.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Mesenchymal Stem Cells

            Therapeutic Area: Infections and Infectious Diseases Product Name: JadiCell

            Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 28, 2020

            Details:

            At 28 days 91% of JadiCell™ treated patients survived whereas only 42% of patients in the placebo group survived. There were no adverse effects associated with JadiCell™ administration.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Mesenchymal Stem Cells

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: JadiCell

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 28, 2020

            Details:

            Using animal models, Company collaborators demonstrated stimulation of stem cell proliferation that reside in parts of the brain called the "dentate gyrus".

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Pterostilbene,Epigallocatechin Gallate,Sulforaphane

            Therapeutic Area: Psychiatry/Psychology Product Name: QuadraMune

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 28, 2020

            Details:

            QuadraMune™ is a nutraceutical developed by the Company which is currently in a clinical trial for prevention of COVID-19[1]. Minocycline is an antibiotic that is approved by the FDA.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Pterostilbene,Epigallocatechin Gallate,Sulforaphane

            Therapeutic Area: Neurology Product Name: QuadraMune

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 28, 2020

            Details:

            Pterostilbene is one of four ingredients which comprise QuadraMune™, a nutraceutical being developed by the Company which is currently in a clinical trial for prevention of COVID-19.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Dendritic Cell Therapy

            Therapeutic Area: Infections and Infectious Diseases Product Name: StemVacs

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 07, 2020

            Details:

            StemVacs™ is based on activating universal donor immune system cells called dendritic cells in a manner so that upon injection they reprogram the body's "Natural Killer" cells.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Dendritic Cell Therapy

            Therapeutic Area: Infections and Infectious Diseases Product Name: StemVacs

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 22, 2020

            Details:

            Company has filed data with the FDA, as part of IND #17448, which demonstrated that treatment of cancer patients with StemVacs™ resulted in enhanced activity of a type of immunological cell called "natural killer" cells, otherwise known as NK cells.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Pterostilbene,Epigallocatechin Gallate,Sulforaphane

            Therapeutic Area: Oncology Product Name: QuadraMune

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 11, 2020

            Details:

            In a series of animal studies using the triple-negative breast cancer 4T1 mouse model, the Company showed that administration of QuadraMune™ reduced lung metastasis on its own and increased efficacy of a “cancer vaccine.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Pterostilbene,Sulforaphane,Epigallocatechin Gallate

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration June 01, 2020

            Details:

            Administration of daily doses of QuadraMune™ in healthy volunteers results in statistically significant increases in immune response activity within 5 days.